SOUTH SAN FRANCISCO, Calif.,
Aug. 13, 2019 /PRNewswire/
-- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced
the pricing of its underwritten public offering of 8,035,715 shares
of its common stock at a price to the public of $28.00 per share. In addition, the underwriters
of the offering have been granted a 30-day option to purchase up to
an additional 1,205,357 shares from Portola at the public offering price. The
offering is expected to close on August 16,
2019, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running
managers. Oppenheimer & Co. Inc. is acting as lead manager for
the offering. A preliminary prospectus supplement and final
prospectus supplement may be obtained from Goldman Sachs & Co.
LLC, Prospectus Department, 200 West Street, New York, NY 10282, by telephone at
866-471-2526, by facsimile at 212-902-9316 or by email at
Prospectus-ny@ny.email.gs.com; Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at 1-800-831-9146; Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus
Department, by telephone at 631-592-5973 or by email at
PostSaleManualRequests@broadridge.com; or William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at
800-621-0687 or by email at prospectus@williamblair.com.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and became
effective on August 7, 2019. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic conditions. The Company's first
two commercialized products are Andexxa® [coagulation factor Xa
(recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet
alfa), and Bevyxxa® (betrixaban). The company also is
advancing cerdulatinib, a SYK/JAK inhibitor being developed for the
treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Forward-Looking Statements
This announcement contains
forward-looking statements, including statements relating to
Portola Pharmaceuticals' expectations regarding the anticipated
closing date. These statements are subject to significant risks and
uncertainties and actual results could differ materially from those
projected. Portola Pharmaceuticals cautions investors not to place
undue reliance on the forward-looking statements contained in this
release. These risks and uncertainties include, without limitation,
risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the public
offering. There can be no assurance that Portola Pharmaceuticals
will be able to complete the public offering on the anticipated
terms, or at all. Risks and uncertainties relating to Portola
Pharmaceuticals and its business can be found in the "Risk Factors"
section of Portola Pharmaceuticals' Quarterly Report on Form 10-Q
for the second quarter of 2019, which was filed on August 7, 2019, and in the preliminary prospectus
supplement related to the proposed offering filed with the SEC.
Portola Pharmaceuticals undertakes no duty or obligation to update
any forward-looking statements contained in this release as a
result of new information, future events or changes in Portola
Pharmaceuticals' expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-300901191.html
SOURCE Portola Pharmaceuticals, Inc.®